No one wants to think that they can’t afford the treatment, and they certainly don’t want to raise that issue with their physician, said Ian Manners, MBA, co-founder, CEO, Vivor.
No one wants to think that they can’t afford the treatment, and they certainly don’t want to raise that issue with their physician, said Ian Manners, MBA, co-founder, CEO, Vivor.
Transcript
With more patient financial assistance programs, does it seem like the stigma of being unable to afford medications is going away?
When done right, this kind of proactive approach really makes a big difference. It’s the difference between waiting for someone to raise their hand and say, “I have a financial problem,” which patients don’t want to do; no one wants to think that they can’t afford the treatment, and they certainly don’t want to raise that issue with their physician, because naturally, like anyone, if you’re diagnosed with cancer, you worry that that means you’re not going to get the best possible treatment, which is what you want the most.
So, what we found is that a really proactive approach of coming to a patient with an answer, instead of a question and a problem, makes a huge difference, saying “I’ve been able to find these solutions for you. They’re not charity, these are just coupons and programs made available by the pharma companies and foundations that are for you, and they can dramatically decrease your out-of-pocket costs. You can put a dollar amount on it.” I think that specificity and that proactive approach really makes a huge difference.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More